Arcus Biosciences, Inc. Increase (Decrease) in Contract with Customer, Asset
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Contract with Customer, Asset of -$5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-08-05
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2026-06-30 was $3.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2026-03-31 was -$8.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2025-09-30 was -$4.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for fiscal 2025 was -$9.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for fiscal 2024 was -$28.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for fiscal 2023 was -$15.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, asset for fiscal 2022 was -$704.00M, a 4241.18% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 3 month as first filed | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 6 month as first filed | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 9 month as first filed | Increase (Decrease) in Contract with Customer, Asset 12 month | Increase (Decrease) in Contract with Customer, Asset 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.00M 10-Q · filed 2026-08-05 | -$5.00M derived: sum of 3 quarters · filed 2026-08-05 | -$9.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$8.00M 10-Q · filed 2026-05-05 | -$8.00M derived: sum of 2 quarters · filed 2026-05-05 | -$12.00M derived: sum of 3 quarters · filed 2026-05-05 | -$12.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$4.00M derived: sum of 2 quarters · filed 2026-02-25 | -$4.00M derived: sum of 3 quarters · filed 2026-08-05 | -$9.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$4.00M derived: sum of 2 quarters · filed 2026-08-05 | -$9.00M 10-Q · filed 2025-10-28 | -$5.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.00M 10-Q · filed 2026-08-05 | -$1.00M derived: sum of 3 quarters · filed 2026-08-05 | -$13.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$5.00M 10-Q · filed 2026-05-05 | -$1.00M derived: sum of 2 quarters · filed 2026-05-05 | -$13.00M derived: sum of 3 quarters · filed 2026-05-05 | -$20.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$8.00M derived: sum of 2 quarters · filed 2026-02-25 | -$15.00M derived: sum of 3 quarters · filed 2026-02-25 | -$28.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | -$12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$19.00M derived: sum of 2 quarters · filed 2025-10-28 | -$32.00M 10-Q · filed 2025-10-28 | -$32.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$20.00M 10-Q · filed 2025-08-06 | -$20.00M derived: sum of 3 quarters · filed 2026-02-25 | -$31.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$13.00M 10-Q · filed 2025-05-06 | -$13.00M derived: sum of 2 quarters · filed 2026-02-25 | -$24.00M derived: sum of 3 quarters · filed 2026-02-25 | -$22.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$11.00M derived: sum of 2 quarters · filed 2026-02-25 | -$9.00M derived: sum of 3 quarters · filed 2026-02-25 | -$15.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | -$11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$9.00M derived: sum of 2 quarters · filed 2024-11-06 | -$15.00M 10-Q · filed 2024-11-06 | -$3.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.00M 10-Q · filed 2024-08-08 | $8.00M derived: sum of 3 quarters · filed 2025-02-25 | $1.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | -$6.00M 10-Q · filed 2024-05-08 | $6.00M derived: sum of 2 quarters · filed 2025-02-25 | -$1.00M derived: sum of 3 quarters · filed 2025-02-25 | $5.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $5.00M derived: sum of 2 quarters · filed 2025-02-25 | $11.00M derived: sum of 3 quarters · filed 2025-02-25 | -$704.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$1.00M derived: sum of 2 quarters · filed 2023-11-07 | -$716.00M 10-Q · filed 2023-11-07 | -$715.81M 10-Q · filed 2022-11-02 | -$698.82M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$709.00M 10-Q · filed 2023-08-07 | -$708.76M 10-Q · filed 2022-08-03 | -$691.82M derived: sum of 3 quarters · filed 2024-02-21 | -$692.53M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | -$715.00M 10-Q · filed 2023-05-09 | -$715.18M 10-Q · filed 2022-05-09 | -$697.82M derived: sum of 2 quarters · filed 2024-02-21 | -$698.53M derived: sum of 3 quarters · filed 2024-02-21 | -$702.19M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $17.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $16.47M derived: sum of 2 quarters · filed 2024-02-21 | $12.81M derived: sum of 3 quarters · filed 2024-02-21 | $17.00M 10-K · filed 2024-02-21 | $17.05M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$704.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$4.36M derived: sum of 2 quarters · filed 2022-11-02 | -$178.00K 10-Q · filed 2022-11-02 | -$1.63M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $526.00K 10-Q · filed 2022-08-03 | -$921.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.44M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $4.19M 10-Q · filed 2022-05-09 | $2.74M derived: sum of 2 quarters · filed 2023-02-28 | $5.10M derived: sum of 3 quarters · filed 2023-02-28 | $4.97M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $910.00K derived: sum of 2 quarters · filed 2023-02-28 | $788.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.00M 10-K · filed 2023-02-28 | $917.00K 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $2.23M derived: sum of 2 quarters · filed 2021-11-08 | $2.45M 10-Q · filed 2021-11-08 | -$2.70M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | -$122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $90.00K 10-Q · filed 2021-08-05 | -$5.05M derived: sum of 3 quarters · filed 2022-02-23 | |||||
| 2020-03-31 | $212.00K 10-Q · filed 2021-05-05 | -$4.93M derived: sum of 2 quarters · filed 2022-02-23 | ||||||
| 2019-12-31 | -$5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $132.00K 10-K · filed 2022-02-23 | ||||||
| 2019-09-30 | $5.28M 10-Q · filed 2020-11-05 | |||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-05 | -$5.00M derived: sum of 2 quarters · filed 2020-05-05 | ||||||
| 2018-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 10-K · filed 2020-03-05 | ||||||
| 2018-09-30 | $5.00M 10-Q · filed 2019-11-05 | |||||||
| 2017-09-30 | $25.00M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |